title: A novel stent coated with antibodies to endoglin inhibits neointimal formation of porcine coronary arteries.
abstract: Endoglin/CD105 is an accessory protein of the transforming growth factor-β receptor system that plays a critical role in proliferation of endothelial cells and neovasculature. Here, we aimed to assess the effect of novel stents coated with antibodies to endoglin (ENDs) on coronary neointima formation. Thirty ENDs, thirty sirolimus-eluting stents (SESs), and thirty bare metal stents (BMSs) were randomly assigned and placed in the coronary arteries in 30 juvenile pigs. Histomorphometric analysis and scanning electron microscopy were performed after stent implantation. Our results showed that after 7 days, there was no difference in the neointimal area and percent area stenosis in ENDs compared with SMSs or BMSs. After 14 days, the neointima area and percent area stenosis in ENDs were markedly decreased than those in BMSs or SESs (P < 0.05). Moreover, the percentage of reendothelialization was significantly higher in ENDs than that in SESs or BMSs (P < 0.01) at 7 and 14 days. The artery injury and the inflammation scores were similar in all groups at 7 and 14 days. In conclusion, our results demonstrated for the first time to our knowledge that endoglin antibody-coated stents can markedly reduce restenosis by enhancing reendothelialization in the porcine model and potentially offer a new approach to prevent restenosis.
authors.affiliation: The Key Laboratory of Remodeling-Related Cardiovascular Diseases, Department of Cardiology, Anzhen Hospital Affiliated to Capital Medical University, Beijing 100029, China.
authors.forename: Song
authors.initials: S
authors.lastname: Cui
authors.affiliation: The Key Laboratory of Remodeling-Related Cardiovascular Diseases, Department of Cardiology, Anzhen Hospital Affiliated to Capital Medical University, Beijing 100029, China.
authors.forename: Jing-Hua
authors.initials: JH
authors.lastname: Liu
authors.affiliation: The Key Laboratory of Remodeling-Related Cardiovascular Diseases, Department of Cardiology, Anzhen Hospital Affiliated to Capital Medical University, Beijing 100029, China.
authors.forename: Xian-Tao
authors.initials: XT
authors.lastname: Song
authors.affiliation: Department of Radiology, China-Japan Friendship Hospital, Beijing 100029, China.
authors.forename: Guo-Lin
authors.initials: GL
authors.lastname: Ma
authors.affiliation: Southern Hospital Affiliated to Southern Medical University, Guangzhou 510515, China.
authors.forename: Ben-Jun
authors.initials: BJ
authors.lastname: Du
authors.affiliation: The Key Laboratory of Remodeling-Related Cardiovascular Diseases, Department of Cardiology, Anzhen Hospital Affiliated to Capital Medical University, Beijing 100029, China.
authors.forename: Shu-Zheng
authors.initials: SZ
authors.lastname: Lv
authors.affiliation: Department of Cardiology, Binzhou Central Hospital, Binzhou 251700, China.
authors.forename: Li-Jun
authors.initials: LJ
authors.lastname: Meng
authors.affiliation: Laboratory of the Animal Center, Academy of Military Medical Sciences, No. 27 Taiping Road, Haidian District, Beijing 100850, China.
authors.forename: Quan-Sheng
authors.initials: QS
authors.lastname: Gao
authors.affiliation: School of Medicine, University of California, San Diego, CA 92103, USA.
authors.forename: Kefeng
authors.initials: K
authors.lastname: Li
mesh_terms: D000818:Animals; D000906:Antibodies / Q000737:chemistry / Q000276:immunology; D015703:Antigens, CD / Q000737:chemistry / Q000276:immunology; D003331:Coronary Vessels / Q000473:pathology*; D004195:Disease Models, Animal; D054855:Drug-Eluting Stents; D000071063:Endoglin; D006801:Humans; D007249:Inflammation / Q000473:pathology / Q000628:therapy*; D058426:Neointima / Q000473:pathology / Q000628:therapy*; D011956:Receptors, Cell Surface / Q000737:chemistry / Q000276:immunology; D013552:Swine
chemical_list: D000906:Antibodies; D015703:Antigens, CD; C064206:ENG protein, human; D000071063:Endoglin; D011956:Receptors, Cell Surface